Marseilles, France

Marc Lopez

USPTO Granted Patents = 8 

 

Average Co-Inventor Count = 2.5

ph-index = 1

Forward Citations = 21(Granted Patents)


Location History:

  • Marseill, FR (2015 - 2022)
  • Marseilles, FR (2002 - 2024)

Company Filing History:


Years Active: 2002-2025

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Marc Lopez

Introduction

Marc Lopez is a prominent inventor based in Marseilles, France. He has made significant contributions to the field of medical research, particularly in the development of antibody drug conjugates for cancer treatment. With a total of 8 patents to his name, Lopez has established himself as a key figure in the innovation landscape.

Latest Patents

Among his latest patents is an antibody drug conjugate (ADC) targeting Nectin 4, which comprises an exatecan payload. This patent provides a detailed disclosure of Nectin-4 ADCs and their pharmaceutical compositions, along with methods for using these ADCs in cancer treatment. Another notable patent focuses on antibodies that have specificity for Nectin-4, emphasizing their potential uses in cancer therapy.

Career Highlights

Marc Lopez has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and the Institut Jean Paoli & Irene Calmettes. His work in these organizations has contributed to advancements in medical research and therapeutic development.

Collaborations

Lopez has collaborated with notable colleagues in his field, including Daniel Olive and Gabriella Campadelli Fiume. These partnerships have further enhanced his research and innovation efforts.

Conclusion

Marc Lopez's contributions to the field of medical research, particularly in cancer treatment, highlight his innovative spirit and dedication to improving healthcare. His patents and collaborations reflect a commitment to advancing scientific knowledge and therapeutic options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…